MEDHOST Achieves Stage 3 Meaningful Use Certification

Continuing its strong streak in Meaningful Use (MU), MEDHOST, a leading provider of enterprise solutions for healthcare management systems, today announced that its Business Intelligence solution has achieved MU Stage 3 certification for Clinical Quality Measures (CQM) 2015.1

 MEDHOST partnered with CitiusTech, a leading provider of healthcare technology services and solutions, to leverage its healthcare BI and analytics capabilities. CitiusTech enabled MEDHOST to enhance its MU Stage 3 certified solution with its advanced CQM capabilities for MU reporting. MEDHOST Business Intelligence is a SaaS-based and a cloud-based executive dashboard, for C-level executives and quality administrators, which helps monitor actionable data for MU reporting. With hundreds of clinical and financial key performance indicators (KPIs) to analyze, Business Intelligence provides deep insight into operational and financial measures, increasing visibility enterprise-wide so that organizations can improve overall facility performance.

 “Attaining Meaningful Use Stage 3 certification is just a part of our larger mission to better equip our clients to provide coordinated care with maximum business efficiency,” said Bill Anderson, Chairman and Chief Executive Officer, MEDHOST. “MEDHOST Business Intelligence solution has extensive capabilities that help our clients meet pay-for-performance requirements, submit outcomes data, perform benchmarking and analytics to optimize clinical and revenue cycle processes, and engage with their clients through intuitive consumer portals.”

 “Delivering fewer medical errors and managing alerting across systems is a key to ensuring effective patient care. Our partnership with MEDHOST has enabled us to build a robust solution which helps ensure clinical accuracy and patient safety, allowing greater ease of electronic flow of information between patients and providers,” said Rizwan Koita, Chief Executive Officer, CitiusTech.

BI-Clinical, CitiusTech’s healthcare BI/ analytics platform, is a certified platform for both provider organizations (e.g. Meaningful Use, PQRS, MIPS/ MACRA) and payer organizations (e.g. NCQA and HEDIS). BI-Clinical consists of a library of more than 600 pre-built KPIs, is deployed over 4,500 locations, supports over 550,000 providers and impacts over 30 million lives.

Gleneagles Global Hospitals releases ‘Painful Wait’

A survey commissioned by Gleneagles Global Hospitals and conducted by CubeX – Sorento reveals the pain points faced by cancer patients and caregivers

  Report Highlights:

·         Overall, Lung Cancer (17%), Breast Cancer (16%), Oral Cancer (15%) and blood cancer (15%) were the most reported cancers in the study

 ·         More than 64 percent of patients in the West were diagnosed with cancer in the second or later stage

 ·         70 percent people had to go through multiple level of testing leading to delay in the onset of treatment

 ·         57 percent patients had to wait for more than 3 months for a confirmed diagnosis

 Gleneagles Global Hospitals today released its ‘Painful Wait’ report that aims at highlighting the difficulties faced by cancer patients during their journey from diagnosis to treatment and thereby identify the key ‘Painful Wait’ areas. This is a national level study commissioned by Gleneagles Global Hospitals in collaboration with CubeX Sorento Health.

The main Painful Wait areas that have been identified include initial symptom recognition and diagnosis, access to cancer diagnostic tests, multiple diagnostic tests, time taken from diagnosis to confirmation, poor access to oncologists, initiation of treatment, satisfaction with hospitals and cost of treatment.

In the area of initial symptom recognition, there is a stark contradiction in the perceived ability of family physicians to understand the symptoms. Respondents in the south (97%) said their family physicians were effective in understanding the symptoms. However, respondents in East (71%), West (69%) and North (47%) opined that their family physicians could not gauge the signs of cancer to correctly route them to specialist. Delay in effectively gauging the signs of cancer at the primary care level delays timely diagnosis and treatment. Hence, the ability of the family physician to gauge early signs of cancer and patient awareness is crucial reported the study.

With regard to screening and diagnosis, less than half the respondents (46%) reported that cancer was detected at stage 1; lowest being in the west (39%) and North (20%) were diagnosed at stage IV. While, 70% respondents got confirmation of diagnosis within 3 months, in west and south the value is low. This indicates the need for faster access to specialized tests and the availability of timely tests results and accurate interpretation to initiate treatment.

 Multiple diagnostic tests were another area of concern. About 7 out of every 10 respondents had to perform several tests on visiting different oncologists. Every respondent in the south (100%) and 70% from the north had to re-do the tests. Poor access to oncologists is a key concern of diagnosis (49%). Faster access to cancer specialists will avoid repeated/multiple tests and agony of patients, commented the study.

Most respondents stated that their expectations from hospitals included accessibility to cancer specialists, quality & expertise of doctors, counseling services, cleanliness & hygiene and all-under-one-roof availability. In the south, especially Chennai, satisfaction level with most parameters while choosing a hospital are higher than other regions. Patient engagement through counseling and timely access to healthcare facilities are clear need gaps to be fulfilled. 

Respondents shared that costly treatment options, re-emergence of cancer, lack of counseling to deal with the emotional stress and access to oncologists were the key areas of concern in their personal experience.

Commenting on the report, Dr. Raja Sundaram, Director – Gleneagles Global Institute of Oncology, Gleneagles Global Health City, Chennai, said, “Painful Wait has given us an indication of the ordeal a cancer patient in India has to go through. The report has shed light on many cracks in the system that affects the proper diagnosis and treatment of cancer in our country. While I am glad that our city according to the report ranks higher on satisfaction while choosing a hospital than the other regions, it is still imperative that we listen to the patients and provide better access to oncologists and counselling to help them deal with emotional stress. I sincerely hope that this study creates awareness and helps the eco-system in India understand the gaps to create a better path to recovery for cancer patients.”         

Dr. Jagprag Singh Gujral, Group COO of Gleneagles Global Hospitals said, “This national survey is an attempt by us to understand a cancer patients journey from diagnosis to treatment and a commitment to streamline the hospitals clinical and operational interfaces to reduce unwarranted stress for the patient and his care takers. The findings are an eye opener and by all means revolutionary for all stakeholders in the healthcare delivery space. We are confident that this new holistic approach that we are introducing in cancer patient care in India will revolutionize the way healthcare delivery providers look at a patient’s journey from symptomatic diagnosis to treatment. “

Mr. Ramesh Krishnan, CEO – India Operations Division, Parkway Pantai said, “According to the Indian Council of Medical Research (ICMR), the projected figure for new cancer cases in 2016 was 14.5 lakh and by 2020, the number is expected to rise exponentially to 17 lakhs.  These numbers are alarming and require collaborative action at both individual and collective levels to make big strides in the fight to cure cancer. We are making a beginning towards serving the unmet needs of patients by creating a pathway, ensuring better patient experience. Through the findings from the research commissioned by us, we will use it to make necessary changes in the way we practice, both clinically and non clinically. Through such initiatives we need to demonstrate control strategies to spread awareness for early detection of cancer and reduce its devastating impact. We also aim to strengthen our resources and provide the best training to meet this increased patient load and deliver quality healthcare”

 The study covers 6 major Indian cities including Bangalore, Mumbai, Delhi, Chennai, Kolkata and Hyderabad. A comprehensive sample of 600 cancer patients and survivors were kind enough to be a part of this study. Insights and feedback was collected through in person interactions with cancer survivors between the ages of 20-55 years old.

Signing of MoU on National Cardiac Life Support Programme – SEMI & AHPI

Signing of MoU on National Cardiac Life Support Programme – SEMI & AHPI

AHPI and SEMI launched National Cardiac Life Support Programme. Knowledge & Training on Basic and Advanced cardiopulmonary resuscitation (CPR) technique is essential for every health care staff in a hospital including doctors,nurses and paramedical staff. The survival chances in cardiac arrest can be drastically improved with Early identification and immediate resuscitation.

In India, very few healthcare providers are formally trained or certified in such resuscitation techniques which could save thousands of lifes. In view of providing such an essential training to all healthcare providers across our country, at their own work place,  The Association of Health Care Providers India (AHPI) have partnered with Society for Emergency Medicine India (SEMI) which is the prime society representing Emergency Medicine in India, for providing a two day cardiac life support program.The program will cover basic and advanced cardiac life support techniques,managing cardiac arrhythmia and providing hands on training in techniques like defibrillation.The training program is also designed to address some of the common problems unique to India including medico legal issues and life support in poisoning, pregnancy, trauma victims & children.

An MOU was signed on 12th January 2017 between AHPI and SEMI in the august presence of presidents and board members of both the associations and the CEO of National Board for Accreditation of Hospitals (NABH).

Vatika to exit its healthcare vertical

The Vatika Group, a leading player in the real estate and hospitality business, has decided to exit its healthcare business- Vatika Medicare.

It was only in January 2015 that the group had announced its foray into healthcare.  The group began its operations in Delhi-NCR by acquiring two diagnostic labs ‘Health Square’ from Spry Hospitality for Rs 30 crore.  Vatika Medicare, which is one of the verticals of Vatika Hotels, had plans of investing Rs 200 crore to open 15 diagnostic centres in tier II cities, beginning with Delhi-NCR. However, the group did not go ahead with rolling out more diagnostic centres.

The group has already exited its diagnostic centre in Gurgaon around 10 months back. The centre was acquired by a group of four doctors.  Its second centre, located in Hauz Khas in Delhi, is likely to be acquired by another group of doctors.

Confirming the news, Deepak Uppal, Director, Vatika Medicare, said, “Yes, we are exiting our healthcare vertical by 31st of this month. We have decided to focus on our core business, which is real estate and hotels.”

Manipal University and IISc Bangalore identify a way to predict DNA defects in IVF derived early embryos using a noninvasive technology

Manipal University and IISc Bangalore identify a way to predict DNA defects in IVF derived early embryos using a noninvasive technology

• Researchers induced DNA lesions experimentally in mouse embryos and observed stark changes in embryo metabolism with high level of DNA damage.

• The Nuclear Magnetic Resonance (NMR) technology was used to detect the metabolic changes in the surrounding growth medium of the embryos.

• The researchers could detect this change 24 hours before the onset of cell death in the embryos.

Manipal, November 21 : Manipal University research received yet another shot in the arm when a team led by Dr Satish Adiga and Dr. Hanudatta Atreya of Indian Institute of Science (IISc) Bangalore identified a way to predict DNA defects in IVF derived early embryos using a noninvasive technology. Scientific Reports, an esteemed British journal from Nature Group has published this innovative finding today. Last week, the University Researchers had discovered the biomolecules that impede surveillance against infection and promote complications in diabetes.
In this study, the researchers induced DNA lesions experimentally in mouse embryos and observed stark changes in embryo metabolism with high level of DNA damage. The Nuclear Magnetic Resonance (NMR) technology was used to detect the metabolic changes in the surrounding growth medium of the embryos. The researchers could detect this change 24 hours before the onset of cell death in the embryos. This may prove to be extremely advantageous when extrapolated to the clinical IVF set up.

The team included Fiona D’Souza, Shubhashree Uppangala, Guruprasad Kalthur and scientists from IISC and National Centre for Biological Sciences (NCBS), Bangalore.

Vice chancellor, Manipal University, Dr H Vinod Bhat said; “This is a significant step forward by our team towards benefiting infertile couples in improving their IVF success”. Dr Adiga who is also an IVF expert said; “The IVF industry all over the world is striving to increase the success rate by applying invasive tests on the embryos. However, there are ethical and other concerns on using such tests on human embryos. We can now efficiently identify embryos with high amounts of DNA lesions and avoid transferring them to patients as they will eventually fail to implant or result in early pregnancy loss”.

“The study brings out how powerful the small molecule metabolites are when it comes to probing changes happening at a macroscopic or cellular level. This opens up new avenues to probe the response of embryos to various external stimuli” said Dr Atreya who is involved in developing biomarker.

The research work is one of the first reports that document how embryos change their metabolism in response to DNA damage in a controlled set up observed in a mouse model. “Previously in the year 2012, our research team was the first in the country to establish this technology to achieve better implantation rates in infertile patients,” said Dr Poornima Baliga, Dean of Kasturba Medical College, Manipal.
Another renowned IVF specialist Dr Pratap Kumar said that the study gave hope to infertile couples as many of them suffered from failed IVF cycles and many a times the reasons were unknown. Indian Funding agencies such as Department of Science and Technology and Indian Council of Medical Research (ICMR) have supported this work.


STEERLife, creator of cutting edge, proprietary continuous processing technology, and Manipal University today announced a partnership to establish a Centre of Excellence dedicated to helping the pharmaceutical and life sciences industry transition from conventional batch processing to continuous processing thereby providing time and cost efficiencies, reducing wastage and delivering greener process. The Centre, located at the Manipal College of Pharmaceutical Sciences (MCOPS) campus, will combine industrial expertise, academic prowess coupled with collaborative in-depth research to develop solutions in highly diversified areas of life sciences that can effectively help the industry battle problems related to regulatory burden, reject rates, time and cost inefficiencies as well as limitations of working with sensitive and valuable materials.

“Under the terms of the partnership STEERLife will provide proprietary co-rotating twin screw technology platform and equipment, sponsor a doctoral research program and impart the requisite training. The Centre will also engage students pursuing their Masters, Doctoral and Postdoctoral studies on research based projects and mentor them in specific areas. As part of this engagement, the identified students will spend time at STEERLife’s Pharmaceutical Development Center in Bengaluru for hands-on industrial experience,” said Mr. Indu Bhushan, Chief Technical Officer, STEERLife.
The initiative comes at a time when regulatory agencies across the globe are increasingly driving the adoption of continuous processing for its numerous advantages related to flexibility, efficiency and the environment. With the Manipal Centre of Excellence being the first of its kind in India, STEERLife, as a part of it’s continuing commitment and efforts to realise its vision of changing the way medicines and nutritional products are made and taken, is also partnering with academic institutions of repute in the US.

Speaking of the partnership, Dr. Babu Padmanabhan, Managing Director and Chief Knowledge Officer, STEERLife and Founder & Promoter, STEER Group, said, “We are honoured to be associated with an institution of the stature of Manipal University. The Centre of Excellence provides a platform for the industry and academia to work together on developing innovative solutions that could transform millions of lives. Our proprietary continuous processing technology helps control shear, remove stagnation and effectively transform characteristics of bio-based and synthesised materials making pharmaceutical products, food, and nutritional products safer and more effective. The technology when coupled with some of the most intelligent minds from Manipal University, can truly help India deliver solutions that are world class and life changing”.

The Centre of Excellence will expose students and researchers to cutting edge technology capable of processing materials of the future without the limitations present in today’s solutions.

Dr. H. Vinod Bhat, Vice Chancellor, Manipal University, said, “Manipal Institutions have long been distinguished for excellence in education. We strive to provide our students with world-class facilities and real-time experiences that can help develop them into global leaders. The Centre of Excellence is one such initiative — where for the first time engineering and pharmaceutical sciences are coming together to give our students access to cutting-edge technology and expertise that has the potential to revolutionise life sciences. We are delighted to partner with STEERLife in making this a reality.”

The STEERLife Manipal Centre of Excellence is likely to commence operations on January 1st, 2017.

Fortis’ SL Raheja Hospital launches ‘The Vocalizer’ for Patients in the ICU

Fortis’ SL Raheja Hospital, Mahim recently unveiled the ‘The Vocalizer’ for patients, an application that helps connect with the patients in the ICU when they can barely talk and move. The brainchild of OncoSurgeon Dr P. Jagannath, this app developed at Fortis’ SL Raheja Hospital itself, will now enable patients in the ICU to communicate with their caregivers and family members far more effectively.

Many patients have an Endotracheal Tube hampering their ability to communicate even though they are conscious. The ‘Vocalizer’ also aids many patients who’ve undergone surgery, who cannot communicate appropriately post-op. Before this advancement in medical communication spectra, caregivers in the hospitals traditionally used generic pre-written notes that helped the patient to communicate but at times those weren’t sufficient since special needs had to be catered to; there was an urgent need to bride this communication gap.

Dr. P Jagganath, Oncosurgeon at SL Raheja Hospital, Mumbai, explained how the app works, “Many patients in the ICU have an endotracheal tube that takes away their ability to speak even though they are conscious. In several cases, we see patients are not able to speak after surgery. The app offers visuals with voiceovers for as many as 60 possible situations in the ICU. This is an effort to enable better communication between the patients and their families as well as the staff in the ICU.”

Dr Sanjith Saseedharan, Head of ICU, Fortis S L Raheja Hospital, Mumbai, who worked alongside Dr P Jagganath to create the app, said “The Vocalizer is a major breakthrough for us, showcasing exemplary usage of technology that can help better healthcare services across the country – this is the start of medical advancement in communication. We are happy to have taken a progressive step towards facilitating better communication between the ICU patients and their caregivers & loved ones.”

With this development, anxious relatives can also stay connected with the patient. The Vocalizer is also available for free download on both iOS and Android, and has been developed by Tata Interactive Systems supported by Crusade Against Cancer Foundation.

Southern region more prone to Gout: An SRL Study

SRL Diagnostics, a leading diagnostic chain in India, released a 3-year data analysis report on Arthritis related tests done on samples received in its labs from across India. According to the report, the 10,000 odd samples tested showed varying degrees of abnormalities in the blood levels of direct and indirect markers of osteoarthritis, rheumatoid arthritis, gout and rheumatic fever. The results varied across four zones of India as well. WhileWestern zone of India showed more abnormalities in the levels of rheumatoid factor- a marker of Rheumatoid Arthritis, Uric acid abnormalities were more common in South zone. Uric acid is a commonly prescribed marker of gout.Data analysed also showed that the East Zone had highest percent of abnormal anti-streptolysin O level- a marker of rheumatic fever and joint disease.

The analysis also found that markers of chronic inflammation-a bodily event that goes on continuously in any chronic joint disease, ESR and CRP were raised in most of the samples than any other marker. This is probably due to the fact that Osteoarthritis (OA) is the most common form of arthritis affecting the population at large.

Furthermore, data showed that abnormal C-Reactive protein (CRP) values were more commonly found in men, while abnormal Erythrocyte Sedimentation Rate (ESR) values were seen more commonly in women.

Dr. Leena Chatterjee, Director Operations SRL Labs & Strategic Initiatives, said, “Bone and joint health are crucial aspects, which are usually ignored by the population at large. Millions in Indiasuffer from bone and joint disorders , but doctor visits for management or laboratory visits for regular check-up and testing remain low. Medical studies have shown that 15-17 per cent of Indian population suffer from some kind of joint disease with Osteoarthritis being on the top. Actually bone and joint disorder is more common than cardiovascular disease and cancer combined. Our 3 year data analysis tries to reiterate this point and also shows that blood based tests can help screen large number of people for common joint diseases

SPAG acquires Giga Health

SPAG, a specialized Public Relations, Public Affairs and Digital Marketing consultancy, today announced the acquisition of Giga Health, a healthcare focused digital marketing and social media agency. The brand will continue to operate as Giga Health under the aegis of the SPAG group.
The move will help SPAG build on expertise, further expand the service offerings and strengthen its presence in the fast evolving pharmaceutical, med-tech and healthcare sector.

With this collaboration, S.P.A.G. is aiming for a big qualitative and quantitative leap in the digital marketing space, a portfolio that is managed by its digital marketing arm, D Yellow Elephant. Aman Gupta, Managing Partner, SPAG, created D Yellow Elephant in early 2015 as a full-service, specialized digital marketing firm focusing on pharmaceutical and life sciences industry. It offers specialized marketing communications services by integrating technology, medical sciences and communications.

Tata Trusts & GE Healthcare partner to skill 10,000 youth for jobs in the healthcare sector

Tata Trusts and GE Healthcare today announced a partnership to train 10,000 youth in various technical areas of healthcare over a three-year period. The partnership will focus on bridging the skills gap in healthcare technical or operating staff. The announcement was made in the presence of Mr. Ratan Tata, Chairman of Tata Trusts, Terri Bresenham, President & CEO, Sustainable Healthcare Solutions, GE Healthcare and Banmali Agrawala, President and CEO, GE South Asia.

GE Healthcare Education Institute (GE HCI) will design, develop and execute these courses through a mix of both classroom training and interactive training exercises. The courses will help people graduate as X-ray, Radiography, Medical equipment, Anesthesia, Operation Theatre and Cardiac Care technicians, as well as Diabetic Education counsellors. The candidates will also undergo continuous assessment and internships during the course of this program. The successful candidates, upon clearing the Healthcare Sector Skills Council (HSSC) exam shall be granted a certification from HSSC.

In the next three years, 10,000 candidates will receive loan scholarships from Tata Trusts upon qualifying for the course. GE will also fund certain candidates on the basis of their eligibility.

It is estimated that the current requirement for allied healthcare professionals (AHP) in India is nearly 6.5 million as against a supply of less than 300,000. As per National Skill Development Corporation, by 2018 the healthcare technician demand-supply gap in India will be 445,000 (84% shortfall).

Speaking on the occasion, R Venkataramanan, Managing Trustee, Tata Trusts said, “At Tata Trusts, making a sustainable difference to lives is the core essence of philanthropy. Tata Trusts aim to drive improvement in healthcare delivery by enabling availability of skilled and motivated healthcare personnel. We believe that this partnership with GE Healthcare will allow many bright young minds, especially women, to come forward and bridge this gap.”